

November 2025

“Over the oxygen supply of the body, carbon dioxide spreads its protecting wings”—Yale University 1935 | VALUE OF INHALATION OF CARBON DIOXIDE IN CLIMBING GREAT ALTITUDES)¹

The medical community has appreciated the life sustaining benefits of delivering carbon dioxide (CO₂) to humans for more than 100 years. Even though LIFE may have found a way to live without oxygen², LIFE simply cannot exist without CO₂. Like water, CO₂ is vital for all life on Earth; and specifically, CO₂ is not a pollutant nor contaminant, and as such, carbon dioxide cannot intoxicate because it exists as a non-poisonous, non-toxic substance.³ Of all the world’s organic compounds, carbon dioxide (by far) represents the most important one for the sustainability of the biosphere (the whole of life on Earth).⁴ Despite its versatility and non-toxic behavior, Mankind has historically had a “love-hate” relationship with CO₂ (e.g., advocates implicating it in “Climate Change”). But notably, physiologically, CO₂ is the body’s most ubiquitous and chief hormone of the body; every tissue produces it, and it likely acts on every organ.⁵ Critical to this discussion, humans are CARBOXYIC BREATHERS, that is, rising CO₂ levels stimulate breathing — NOT falling O₂ levels.

To list just a few conditions that Mankind (with decades of literature support) has successfully, and therapeutically, utilized delivered CO₂:

1. Altitude Sickness^{1,6,7,8}
2. Central Sleep Apnea^{9,10,11,12}
3. Obstructive Sleep Apnea^{13,14,15}
4. Orthostatic Intolerance & Postural Orthostatic Tachycardia Syndrome¹⁶
5. Seizures^{17,18,19}
6. Migraines²⁰
7. Congestive Heart Failure²¹
8. Carbon monoxide poisoning^{22, 23}
9. Improved exercise physiology²⁴
10. Improving Cerebral Blood Flow and cerebral hypoxia^{25, 26}

—Notably, all scenarios utilized CANISTER—delivered CO₂! In fact, contrary to finding harmful effects of mildly elevated CO₂ (i.e., HYPERcapnia), ample evidence exists of great harm when CO₂ levels drop (i.e., HYPOcapnia).^{27,28,29,30,31}

Delivery of up to 180-pound canisters of CO₂ therapeutic gas to subjects/consumers represents the overwhelming historical obstacle to commercialization of CO₂ therapies, as well as how to satisfy the FDA’s valid concerns over its purity and safety of delivery. DeltaChase utilizes biomimicry (looking to Nature) to solve this conundrum. Following the lead of many CO₂ modulating animals, we fashioned a 3 oz “dead space” rebreathing apparatus, called the SAGE Rebreather™, which cleverly positions precise volumes of exhaled CO₂ gas within the respiratory column for rebreathing in the next inhalation. “Columns of flow” enable a feedback loop in mixing expired and ambient air, based on laminar versus turbulent flow. Moreover, proprietary algorithms (based on the subject’s weight in conjunction with the desired levels of CO₂) allow us to offer customized rebreathed volumes of captured exhaled gasses, thereby locking the body into new

and improved homeostatic levels of CO₂. In most cases, therapeutic modulation occurs without even making the body's CO₂ rise out of its normal range — typically, just riding at the top of the normal range.

For clarity, this technology allows decades of vetted and corroborated CO₂ research, including safety to emerge from the “laboratory” to afford amazing benefits heretofore never deemed possible. As Rebreather Masks are not novel, (having been around for 70 years), our SAGE Rebreather registers with the FDA as a Class I 510 (k) EXEMPT from premarket notification; this means we enjoy an enviable smooth regulatory pathway to commercialization. On the other hand, the ability of our SAGE to “lock-in” specific CO₂ levels and not allow “run-away” CO₂ levels to occur (i.e., conceptually “fail-safe”) frames our patentability. Future clinical trials need only develop data for new marketing claims, but not safety nor general efficacy.

In our CO₂ journey, a recent epiphany realized that many animals modulate themselves to higher CO₂ levels and seem to be highly resistant to many infectious pathogens (like Malaria and COVID-19). In fact, bats (that live in 6% CO₂) carry 80+ malaria species and over 450 Coronaviruses, without any apparent harm. Even though mosquitos (the main vector in Malaria) are their major source of nutrition, you would be hard pressed to ever find a bat dying of any form of malaria. Also, COVID-19 patients often present with LOW CO₂ levels and poor ventilation, so driving patients to VENTILATE with CO₂, as well as oxygenate, should dramatically improve the plight of the infected. Further, “we postulate a mechanism of action,” whereby adding a higher inhaled CO₂ could/should reduce the virulence, viral load and perhaps the viral shedding of those treated by our SAGE Rebreather (discussion available but beyond the scope of this missive).

Measles, mumps, polio, and chickenpox are all examples of infectious diseases that were once very common but are now rare in the U.S. because vaccines helped to establish herd immunity. To develop this herd immunity, the “herd” MUST NOT DIE of the infection (which enables antibody production). We believe our technology can help those who contract the virus by improving their respiratory parameters, including respiratory rate, O₂ and CO₂ levels, work of breathing, sense of well-being, and extending the time-course to needing transfer to ICU care (if needed at all). We contemplate secondary studies testing the hypothesis that elevated CO₂ levels could also reduce viral loads, viral shedding, and mortality from COVID-19 infections. As the mechanism of action could correlate to other viral infections, these benefits may also join the fight against future pandemics (and even Malaria).

David Smith MD (DrDave™)
Chief Science Officer
Delta Chase LLC

FOOTNOTES

- ¹ Possible Value of Inhalation of Carbon Dioxide in Climbing Great Altitudes, SAMUEL B. CHILDS, Jr., HANNIBAL HAMLIN, YANDELL HENDERSON, Laboratory of Applied Physiology, Yale University, MARCH 23, 1935, NATURE pp 457
- ² A cnidarian parasite of salmon (Myxozoa: *Henneguya*) lacks a mitochondrial genome, Dayana Yahalomi, Stephen D. Atkinson, Moran Neuhof, E. Sally Chang, Hervé Philippe, Paulyn Cartwright, Jerri Bartholomew, Dorothée Huchon, Proceedings of the National Academy of Sciences Mar 2020, 117 (10) 5358-5363; DOI:10.1073/pnas.1909907117
- ³ CARBON DIOXIDE AND HUMAN HEALTH, Nasif Nahle, http://www.biocab.org/Carbon_Dioxide_CO2.html#anchor_20
- ⁴ Carbon Dioxide and Life, Adep Said, http://www.biocab.org/Carbon_Dioxide_CO2.html#anchor_20
- ⁵ Y. Henderson, "Carbon Dioxide," Cyclopedia of Medicine, 1940.
- ⁶ Effect of carbon dioxide in acute mountain sickness: A rediscovery, Harvey TC, Winterburn MH, Lussen NA, et al, Lancet 639-641, Sep 1988
- ⁷ Carbon dioxide contributes to the beneficial effect of pressurization in a portable hyperbaric chamber at high altitude, Christopher H. E. IMRAY, Timothy CLARKE, Peter J. G. FORSTER, Timothy C. HARVEY, Helen HOARS, Sarah WALSH, Alexander D. WRIGHT, Clinical Science (2001) 100, 151–157 (Printed in Great Britain)
- ⁸ Dead Space Mask Eliminates Central Apnea at Altitude, David S. Patz, M.D., Michael D. Patz, M.D., and Peter H. Hackett, M.D., HIGH ALTITUDE MEDICINE & BIOLOGY, Volume 14, Number 2, 2013
- ⁹ REVIEW, Dempsey JA. Central sleep apnea: misunderstood and mistreated! [version 1; peer review: 2 approved], F1000Research 2019, 8(F1000 Faculty Rev):981 (<https://doi.org/10.12688/f1000research.18358.1>)
- ¹⁰ Effects of inhaled CO₂ and added dead space on idiopathic central sleep apnea, AILIANG XIE, FIONA RANKIN, RUTH RUTHERFORD, AND T. DOUGLAS BRADLEY, 0161-7567/97 1997 the American Physiological Society
- ¹¹ Dead Space Mask Eliminates Central Apnea at Altitude, David S. Patz, M.D.,^{1,2} Michael D. Patz, M.D.,³ and Peter H. Hackett, M.D., HIGH ALTITUDE MEDICINE & BIOLOGY, Volume 14, Number 2, 2013
- ¹² Treatment of Cheyne-Stokes respiration with nasal oxygen and carbon dioxide, S. Andreas, K. Weidel. G. Hagenah, S. Heindl, Eur Respir J 1998; 12: 414–419
- ¹³ The ventilatory responsiveness to CO₂ as a determinant of ventilatory stability in sleep, Jerome Dempsey, j physiol 560.1 (2004), pp 1-11
- ¹⁴ Physiology in Medicine: Obstructive sleep apnea pathogenesis and treatment—considerations beyond airway anatomy, Jerome Dempsey, J Appl Physiol (1985). 2014 Jan 1; 116(1): 3–12.
- ¹⁵ Effect of improved nasal breathing on obstructive sleep apnea, Otolaryngology–Head and Neck Surgery, 72 FRIEDMAN et al January 2000
- ¹⁶ The effects of breathing 5% CO₂ on human cardiovascular responses and tolerance to orthostatic stress, Reuben Howden, J. Timothy Lightfoot, Stephen J. Brown, and Ian L. Swaine, Exp Physiol 89.4 pp 465–471
- ¹⁷ Five Percent CO₂ Is a Potent, Fast-Acting Inhalation Anticonvulsant., Tolner EA, Hochman DW, Hassinen P, Otáhal J, Gaily E, Haglund MM, Kubová H, Schuchmann S, Vanhatalo S, Kaila K. Epilepsia 2011;52(1):104–114.
- ¹⁸ 5% CO₂ inhalation suppresses hyperventilation-induced absence seizures in children Xiao-Fan Yang, Epilepsy Research (2014)108,345–348
- ¹⁹ Seizure Termination by Acidosis Depends on ASIC1a. Ziemann AE, Schnizler MK, Albert GW, Severson MA, Howard MA3rd, Welsh MJ, Wemmie JA. Nat Neurosci 2008;11(7):816–822.

- ²⁰ Snorting Carbon Dioxide May Relieve Migraines, nearly 1/3 of Sufferers Pain-Free Within 2 Hours, Charlene Laino, 2005 WEBMD, American Neurological Association 130th Annual Meeting, San Diego, Sept. 25-28, 2005. Egilius Spierings, MD, PhD, associate clinical professor of neurology, Harvard Medical School, Boston; medical director, Capnia Corp., Mountainview, Calif. John Clause Krusz, MD, PhD, medical director, Anodyne Headache and Pain Care, Dallas.
- ²¹ Effect of Inhaled 3% CO₂ on Cheyne-Stokes Respiration Congestive Heart Failure, Rodney D. Steens, Thomas W. Millar, Su Xiaoling, Darren Biberdorf, Patricia Buckle, Mansoor Ahmed and Meir H. Kryger, *Sleep*, 17(1):61-68
- ²² Rapid elimination of CO through the lungs: coming full circle 100 years on, Joseph A. Fisher, Steve Iscoe, Ludwik Fedorko and James Duffin, *Exp Physiol* 96.12 pp 1262–1269
- ²³ Isocapnic Hyperpnea Accelerates Carbon Monoxide Elimination, JOSEPH A. FISHER, JOSHUA RUCKER, LEEOR Z. SOMMER, ALEX VESELY, ELANA LAVINE, YOEL GREENWALD, GEORGE VOLGYESI, LUDWIK FEDORKO, and STEVE ISCOE, *AM J RESPIR CRIT CARE MED* 1999;159:1289–1292
- ²⁴ Respiratory adaptations to dead space loading during maximal incremental exercise, COLM MCFARLAND, JOSEPH MINK, AND CHARLES G. GALLAGHER, Section of Respiratory Medicine, Department of Medicine, University of Saskatchewan, American Physiological Society, 1991, 0161-7567/91 pp 55-62
- ²⁵ Carbon dioxide induced changes in cerebral blood flow and flow velocity: role of cerebrovascular resistance and effective cerebral perfusion pressure Frank Grüne, Stephan Kazmaier², Robert J Stolker, Gerhard H Visser and Andreas Weyland, *Journal of Cerebral Blood Flow & Metabolism* (2015) 35, 1470–1477
- ²⁶ Relationship between middle cerebral artery blood velocity and end-tidal PCO₂ in the hypocapnic-hypercapnic range in humans, Kojiro Ide, Michael Eliasziw, and Marc J. Poulin, *J Appl Physiol* 95: 129–137, 2003.
- ²⁷ SOME ADVERSE PHYSIOLOGICAL EFFECTS OF HYPOCARBIA AND METHODS OF MAINTAINING NORMOCARBIA DURING CONTROLLED VENTILATION-A REVIEW, BRIAN POLLARD AND DAVID B. GIBB, *Anaesth. Intens. Care* (1977). 5, 113
- ²⁸ Hypocarbica and Adverse Outcome in Neonatal Hypoxic-Ischemic Encephalopathy, Athina Pappas, MD, Seetha Shankaran, MD, Abbot R. Lupton, MD, John C. Langer, MS, Rebecca Bara, RN, Richard A. Ehrenkranz, MD, Ronald N. Goldberg, MD, Abhik Das, *J Pediatr*. 2011 May; 158(5): 752–758.e1. doi: 10.1016/j.jpeds.2010.10.019.
- ²⁹ HYPOCAPNIA, JOHN LAFFEY, M.D., AND BRIAN P. KAVANAGH, M.B. REVIEW ARTICLE, *N Engl J Med*, Vol. 347, No. 1, July 4, 2002
- ³⁰ Hypocapnia and the injured brain: More harm than benefit, Gerard Curley, MB, FCARCSI; Brian P. Kavanagh, MD, FRCPC; John G. Laffey, MD, MA, BSc, FCARCSI, REVIEW ARTICLE, *Crit Care Med* 2010 Vol. 38, No. 5
- ³¹ Hypocapnia and Asthma, A Mechanism for Breathing Retraining? Anne Bruton, PhD; and Stephen T. Holgate, DSc, *CHEST* 2005; 127:1808–1811